SPECTROBID
Clinical safety rating: caution
Comprehensive clinical and safety monograph for SPECTROBID (SPECTROBID).
Spectrobird (bacampicillin) is a prodrug of ampicillin, a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.
| Metabolism | Bacampicillin is hydrolyzed by esterases in the intestinal wall and liver to active ampicillin. Ampicillin is partially metabolized by the liver and renal excretion is the primary route of elimination. |
| Excretion | Renal: ~75-85% unchanged drug; fecal/biliary: ~15-25% as metabolites and unchanged drug. |
| Half-life | Terminal elimination half-life: 1.5-2 hours in normal renal function; prolonged to 6-10 hours in severe renal impairment (CrCl <10 mL/min). |
| Protein binding | 15-25% bound to serum albumin. |
| Volume of Distribution | Vd: 0.3-0.4 L/kg; distributes primarily into extracellular fluid. |
| Bioavailability | Oral: 90-100% (as bacampicillin); IM: nearly 100% (as ampicillin sodium). |
| Onset of Action | Oral: 1-2 hours; Intramuscular: 30-60 minutes; Intravenous: immediate. |
| Duration of Action | Oral: 6-8 hours; IM/IV: 6-12 hours; clinical duration may be extended in renal impairment. |
| Molecular Weight | 575.6 Da (as bacampicillin hydrochloride) |
400 mg orally twice daily or 200 mg orally four times daily for 10-14 days. For acute exacerbations of chronic bronchitis: 400 mg orally twice daily for 10 days.
| Dosage form | FOR SUSPENSION |
| Renal impairment | CrCl >80 mL/min: no adjustment. CrCl 50-80 mL/min: 400 mg orally every 12 hours. CrCl <50 mL/min: 400 mg orally every 24 hours. |
| Liver impairment | No adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Not studied in severe hepatic impairment (Child-Pugh C); use with caution. |
| Pediatric use | Children ≥8 years: 4-8 mg/kg/day orally in 2 divided doses, not to exceed 400 mg/day. For uncomplicated skin infections: 200 mg orally twice daily. Duration: 7-14 days. |
| Geriatric use | No specific dose adjustment based solely on age. Consider renal function; if CrCl <50 mL/min, adjust per renal guidelines. Monitor for increased risk of adverse effects such as QT prolongation and Clostridium difficile infection. |
| 1st trimester | Category B: No evidence of risk in humans, but adequate studies in pregnant women are lacking. Use only if clearly needed. |
| 2nd trimester | Category B: No evidence of risk in humans; considered safe during second trimester if indicated. |
| 3rd trimester | Category B: Avoid use near term due to potential risk of kernicterus in neonates, especially if premature, as it is a penicillin antibiotic. |
Clinical note
Comprehensive clinical and safety monograph for SPECTROBID (SPECTROBID).
| Placental transfer | Bacampicillin, as a prodrug of ampicillin, crosses the placenta. Measurable concentrations are found in fetal blood and amniotic fluid. The transfer is similar to ampicillin, which is known to cross the placenta readily. |
| Breastfeeding | Spectrobid (bacampicillin) is excreted into breast milk in low concentrations. It is generally considered compatible with breastfeeding, but caution is advised in infants with hypersensitivity to penicillins or those with gastrointestinal disturbances. |
■ FDA Black Box Warning
Serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported in patients on penicillin therapy. Before initiating therapy, careful inquiry should be made concerning previous hypersensitivity reactions to penicillins, cephalosporins, or other allergens.
| Serious Effects |
Hypersensitivity to bacampicillin, ampicillin, or any penicillinHistory of anaphylactic reaction to beta-lactam antibioticsInfectious mononucleosis (high risk of maculopapular rash)
| Precautions | Serious hypersensitivity reactions (including anaphylaxis) may occur. Prolonged use may result in superinfection. Caution in patients with renal impairment (dose adjustment required). May cause antibiotic-associated colitis. Use cautiously in patients with mononucleosis due to high incidence of rash. |
| Food/Dietary | Food decreases absorption; take on an empty stomach. Avoid alcohol during treatment. |
Loading safety data…
| Lactation Rating | L2: Probably Compatible (limited to moderate data, but no increased risk). |
| Teratogenic Risk | Spectrobid (bacampicillin) is a prodrug of ampicillin. Generally, penicillins are considered low risk during pregnancy. Animal studies have not shown teratogenic effects. In humans, adequate studies in pregnant women have not been conducted, but data from extensive use of ampicillin do not indicate an increased risk of congenital malformations. First trimester: limited data, but no evidence of teratogenicity. Second and third trimesters: considered safe when clinically indicated. Risk category: B (U.S. FDA). |
| Fetal Monitoring | Monitor maternal renal function (creatinine clearance) as dosage adjustment may be needed in severe renal impairment. No specific fetal monitoring required; routine prenatal care including fetal growth assessment as per standard guidelines. Observe for signs of maternal hypersensitivity reactions or gastrointestinal disturbances. |
| Fertility Effects | No known adverse effects on human fertility. Animal studies have not shown impaired fertility at therapeutic doses. Limited human data, but penicillins are generally not associated with fertility impairment. |
| Clinical Pearls | Spectrobid (bacampicillin) is a prodrug of ampicillin with improved oral bioavailability. It is dosed twice daily due to prolonged absorption. Useful for respiratory tract infections, otitis media, urinary tract infections, and skin infections caused by susceptible strains. Cross-allergenicity with other penicillins; contraindicated in penicillin allergy. May cause false-positive urine glucose tests with Clinitest but not with glucose oxidase methods (e.g., Clinistix). Administer on an empty stomach for maximal absorption. |
| Patient Advice | Take this medication exactly as prescribed, usually twice daily. · Take on an empty stomach, at least 1 hour before or 2 hours after a meal. · Complete the full course of therapy even if you feel better. · Inform your doctor if you have a history of penicillin allergy. · Report any severe diarrhea, rash, or difficulty breathing immediately. · Store at room temperature away from moisture and heat. · This medication may cause false-positive urine glucose tests; inform your healthcare provider if you have diabetes. |